Ma Xuegong, Wang Yingmei, Zhang Xuhong, Dong Mengting, Yang Wen, Xue Fengxia
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, China.
Cancer Biol Med. 2018 May;15(2):182-187. doi: 10.20892/j.issn.2095-3941.2018.0009.
Hypercalcemia presenting in ovarian cancer is uncommon in the clinic. Here, two cases of ovarian epithelial carcinoma that presented with severe hypercalcemia were reported, with a review of the literature. The laboratory findings and stepwise clinical investigations of these two cases differed, indicating distinct underlying causes of hypercalcemia. In case one, the serum levels and immunostaining for parathyroid hormone-related protein (PTHrP) verified humoral hypercalcemia of malignancy (HHM). In case two, the high level of parathyroid hormone (PTH) and the scintigraphy scan showing parathyroid gland adenoma confirmed primary hyperparathyroidism-induced hypercalcemia. Both patients received optimal cytoreductive operation and adjuvant chemotherapy but showed different outcomes respectively. This article focused on differential diagnosis of ovarian cancer-associated hypercalcemia, by stepwise imaging and laboratory investigation, and the appropriate therapy should be considered based on the different etiologies.
高钙血症在卵巢癌临床中并不常见。本文报告了两例表现为严重高钙血症的卵巢上皮癌病例,并对相关文献进行了综述。这两例病例的实验室检查结果和逐步的临床研究有所不同,提示高钙血症的潜在病因各异。病例一,血清水平及甲状旁腺激素相关蛋白(PTHrP)免疫染色证实为恶性肿瘤体液性高钙血症(HHM)。病例二,甲状旁腺激素(PTH)水平升高及甲状旁腺腺瘤闪烁扫描证实为原发性甲状旁腺功能亢进所致高钙血症。两名患者均接受了最佳减瘤手术及辅助化疗,但分别显示出不同的预后。本文通过逐步的影像学和实验室检查,重点关注卵巢癌相关高钙血症的鉴别诊断,并应根据不同病因考虑适当的治疗方法。